Acceder

Análisis técnico y gráfico histórico de Affimed N.V.

Análisis fundamental y estadísticas clave de Affimed N.V.

Ficha de Affimed N.V. (AFMD)

Ticker AFMD
ISIN NL0015001ZQ0
Sector Atención sanitaria
Mercado NASDAQ

Análisis financiero de Affimed N.V.

Briefing Valoración Rentabilidad Métricas por acción Deuda Liquidez

Resumen financiero e información corporativa de Affimed N.V.

Invertir en Affimed N.V. en 2026: Preguntas frecuentes

¿Qué es Affimed N.V.?

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in Phase I clinical trial for hodgkin lymphoma. The company is also developing AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16...

¿En qué sector opera Affimed N.V.?

Affimed N.V. opera en el sector Healthcare, industria Biotechnology.